COPD

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

Explore how advanced practice practitioners enhance COPD care through innovative models, improving patient outcomes and addressing rural healthcare challenges.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

A form of the cytisine regimen, widely used in Eastern Europe for decades, is finally being put in front of US regulators after recently also becoming available in the UK.

Discover how advancements in biologic therapies and precision medicine are transforming asthma and COPD management, enhancing patient care and outcomes.

Explore the latest advancements in biologic therapies for asthma and COPD discussed in a recent clinical forum highlighting personalized medicine and biomarker-driven strategies for improved patient outcomes.

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.

Gerard Criner, MD, spells out GOLD improvements, from interventions like smoking cessation and pulmonary rehabilitation to the heightened importance of spirometry for diagnosis.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.

The analysis of pooled data from BOREAS and NOTUS highlight dupilumab’s sustained impact on lung function in patients with COPD and type 2 inflammation.

The FDA approves mepolizumab as a new maintenance treatment for COPD, showing significant reduction in exacerbations for specific patients.

Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of the drug, if approved.

Stoller describes the potential of a novel AI model to help address AATD underrecognition, citing findings from his research on its performance in a Cleveland Clinic cohort.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

The pooled analysis of ENHANCE clinical trial program data highlight improvements in HRQoL, dyspnea, and COPD symptoms with ensifentrine monotherapy.

Associations were particularly strong for people with severe COPD.

Vapendavir shows promise in reducing respiratory symptoms and illness duration in COPD patients infected with rhinovirus.

New research follows a previous landmark study that linked mucus plugs to increased mortality in people with COPD even without hallmark symptoms.

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.